About this medicine

Long-lasting active metabolites make the medicine’s response to a dose change slower than the dosing interval suggests.

Cariprazine is a second-generation antipsychotic. This UK article concerns Reagila for adult schizophrenia, not the broader Vraylar indications described in the USA edition. Improvement, adverse effects and changes in day-to-day functioning need to be followed together over time.

What is this medicine used for?

The UK Reagila licence covers adult schizophrenia. US Vraylar indications are not UK authorisation.

The current UK indication does not include the American paediatric schizophrenia or bipolar-mania approvals, bipolar depression or adding treatment for major depression. A clinician considering another use must identify it as off-label; a shared mechanism does not extend the UK licence.

Which warning signs need help?

Fever, marked rigidity and confusion require urgent assessment. Chest pain or breathing difficulty may indicate a clot. Report severe unexplained muscle pain or weakness.

New involuntary movements should be reported early because some can persist. Marked sedation, fainting or new suicidal thoughts also need prompt assessment. Immediate danger, collapse or suspected overdose requires urgent local emergency care.

How do I take it safely?

The labelled start is 1.5 mg daily, with gradual 1.5 mg increases when appropriate, up to 6 mg. Full effects of changes may take weeks.

Take the prescribed capsule once daily at a consistent time, with or without food. The four checked UK strengths are 1.5, 3, 4.5 and 6 mg; lower American paediatric strengths are not imported into this UK panel. Monitoring continues after each change because later accumulation can reveal adverse effects.

What side effects should I know about?

Sleep disturbance, anxiety, nausea, constipation, sleepiness and weight gain are among reported effects.

Record movement symptoms, sleep and daily functioning rather than looking only at whether hallucinations or other symptoms have reduced. Some adverse effects can appear after several apparently stable days, and persistent effects after a reduction do not necessarily mean that the change has had no pharmacological effect.

Who needs extra care with this medicine?

Severe kidney or liver impairment requires specialist assessment; the product is not recommended in these situations or for dementia-related psychosis.

Parkinson's disease, seizure history, stroke risk and cardiovascular disease require particular assessment. New visual symptoms warrant an eye examination: animal lens findings do not prove that cariprazine causes cataracts in every human, but the label advises evaluating possible symptoms.

Can it affect my other medicines?

Strong CYP3A4 inhibitors and strong or moderate inducers are contraindicated. Moderate inhibitors require monitoring and possible dose reduction under the current label. Avoid grapefruit and alcohol.

CYP3A4 participates in both producing and clearing active substances. That is why the interaction cannot always be reduced to a simple prediction about the parent drug alone. The current UK distinction between strong and moderate inhibitors must be preserved; older wording and US low-strength dose tables are not substitutes.

What check-ups will I need?

Follow symptoms and movement effects after dose changes. Check weight, blood pressure, glucose and lipids; include other antipsychotic monitoring according to risk.

What about pregnancy, breastfeeding and age?

Use effective contraception during treatment and for at least ten weeks afterwards. Discuss pregnancy immediately. The leaflet advises against breastfeeding; use under 18 is not recommended.

What if I miss a dose or want to stop?

Do not double a missed dose. Discuss stopping with the prescriber because medicine and metabolites persist after treatment ends.

A long half-life is not permission to skip doses or overlap treatments independently. The team needs the date of the last dose and any recent interacting medicines when planning a switch. Continuing follow-up after stopping matters because clinically active substances remain.

How does it work?

Cariprazine partly activates dopamine D3 and D2 receptors, proteins that receive messages from dopamine, a chemical messenger. This is called partial agonism: the medicine activates a receiving site but produces a smaller response than a full activator under comparable conditions. D3 and D2 name particular types of dopamine receptor.

What happens in a living brain also depends on the chemical messages already present and the activity of connected cells. Cariprazine has actions at receptors for serotonin, another chemical messenger, and the complete connection between its receptor effects and improvement in symptoms remains uncertain. These findings do not establish a simple dopamine shortage or excess that can be measured to choose a person’s treatment.

How does it affect my body?

Inner restlessness, difficulty staying still and parkinsonian movement symptoms are particularly relevant tolerability problems.

Higher laboratory affinity for D3 than D2 receptors does not prove superior clinical benefit for a particular person. Inner restlessness can resemble worsening anxiety or agitation; automatically increasing treatment may miss an adverse effect. Tell the team about a new inability to sit still.

How does my body process it?

CYP3A4 produces active metabolites that persist after the last dose. CYP2D6 makes a smaller contribution.

The combined parent-and-metabolite exposure approaches steady levels over several weeks. The UK label gives an effective half-life of about a week for the total active substances, with total concentrations falling by about half a week after stopping. A once-daily capsule does not imply its action ends within a day.

How do treatment options differ?

Its slow elimination matters during treatment changes, which require clinical planning.

Aripiprazole also has partial-agonist actions, but this does not establish equivalent dose, indication, formulation or response timing. Cariprazine's long-lived metabolites are a practical distinction; receptor-affinity rankings alone are not a way to choose between medicines.

A closer look at the science

Its receptor actions also include partial stimulation of 5-HT1A and antagonism at several serotonin receptors.

The capsule contains cariprazine hydrochloride, with strength expressed as cariprazine. Its active breakdown products desmethylcariprazine and didesmethylcariprazine are not identical to the parent molecule. Receptor binding and chemical structure explain scientific identity, not which dose a particular person requires.

How was this medicine developed?

The verified UK capsule information was revised in February 2026. This article uses that revision’s interaction rules.

The two editions illustrate divergent regulatory development: additional American indications and ages do not automatically change Reagila's UK licence. The dated UK product source, rather than a brand-name search match, governs the regional account.

Sources and References

  1. Reagila hard capsules — UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  2. Reagila 1.5 mg, 3 mg, 4.5 mg and 6 mg capsules — UK patient leaflet

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  3. Psychosis and schizophrenia in adults: recommendations

    Scope: NICE guidance (England-based); applicability and implementation in other UK nations require the relevant national pathway.

  4. Vraylar (cariprazine): prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: 12.1 Mechanism of Action; 12.2 Pharmacodynamics; 12.3 Pharmacokinetics. This does not establish UK product authorisation or prescribing..

  5. Schizophrenia
  6. NIMH: Understanding psychosis

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top